CoChat

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Published version of a preprint

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms including compensatory ligand upregulation and de novo gene alterations. Sym004 is a two-antibody mixture targeting nonoverlapping EGFR epitopes. In preclinical models, Sym004 causes significant EGFR internalization and degradation, which translates into superior growth inhibition in the presence of ligands. In this phase I trial, we observed grade 3 skin toxicity and hypomagnesemia as mechanism-based dose-limiting events during dose escalation. In dose-expansion cohorts of 9 and 12 mg/kg of Sym004 weekly, patients with metastatic colorectal cancer and acquired EGFR inhibitor resistance were enrolled; 17 of 39 patients (44%) had tumor shrinkage, with 5 patients (13%) achieving partial response. Pharmacodynamic studies confirmed marked Sym004-induced EGFR downmodulation. MET gene amplification emerged in 1 patient during Sym004 treatment, and a partial response was seen in a patient with EGFRS492R mutation that is predictive of cetuximab resistance. Significance: Potent EGFR downmodulation with Sym004 in patients with metastatic colorectal cancer and acquired resistance to cetuximab/panitumumab translates into significant antitumor activity and validates the preclinical hypothesis that a proportion of tumors remains dependent on EGFR signaling. Further clinical development and expanded correlative analyses of response patterns with secondary RAS/EGFR mutations are warranted. Cancer Discov; 5(6);598–609. ©2015 AACR. See related commentary by Stintzing and Heinemann, p. 578 This article is highlighted in the In This Issue feature, p. 565

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-1432

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Cited by

See all 85

Metadata

Authors
Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., Hansen, U. H., Hald, R., Pedersen, M. W., Kragh, M., Horak, I. D., Braun, S., Van Cutsem, E., Tolcher, A. W., & Tabernero, J.
Affiliations
  • Universitat Autònoma de Barcelona (ES)
  • South Texas Accelerated Research Therapeutics (US)
  • 4Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (HUVR, CSIC, Universidad de Sevilla), Center affiliated to the RTICC (ISCiii), Sevilla, Spain.
  • 5Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Consejo Superior de Investigaciones Científicas (ES)
  • Universitat de València (ES)
  • Radboud University Medical Center (NL)
  • 6Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Symphogen (Denmark) (DK)
  • 8Digestive Oncology Department, University Hospitals Leuven and KULeuven, Leuven, Belgium.
Corresponding author
Tabernero, Josep
Venue
Cancer Discovery
Published
2015-06-01
Volume
5
Issue
6
Pages
598-609
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2130584549
Cited by
77
References
28
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 13 · 2017: 13 · 2016: 15 · 2015: 9
FWCI
7.28
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Funders
  • European Commission
  • Symphogen
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
metastatic colorectal cancer, EGFR inhibitor resistance, cetuximab resistance, MET amplification, skin toxicity, hypomagnesemia, dose-limiting toxicity, tumor shrinkage, RAS mutations
MeSH terms
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Gene Amplification, Humans, Ligands, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Treatment Outcome, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Class I Phosphatidylinositol 3-Kinases, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-14-1432
The paper
Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., Hansen, U. H., Hald, R., Pedersen, M. W., Kragh, M., Horak, I. D., Braun, S., Van Cutsem, E., Tolcher, A. W., & Tabernero, J. (2015). Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-14-1432

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.